Global Plasma Therapy Market Outlook 2030

The global plasma therapy market in 2021 is estimated to be ~USD 480 million, and it is expected to expand at a compound annual growth rate (CAGR) of 13% from 2022 to 2030. It has been proven that platelet-rich plasma (PRP) is an important source of autologous products in the field of regenerative medicine and a true pioneer in the healing process together with scaffolds and stem cells. It is expected that the increase in the incidence of sports injuries and orthopedic diseases will drive the demand for PRP therapy. The expanding research base is expected to drive demand for platelet-rich plasma preparation products.

In recent years, PRP products have become more and more common in the treatment of musculoskeletal diseases, orthopedic diseases and sports injuries. Several studies have observed that increasing the concentration of growth factors in platelet-rich plasma may accelerate the healing process. This has proven to be an important source of autologous products in the field of regenerative medicine and a true pioneer in the healing process with stem cells and scaffolds.

According to data from the Centers for Disease Control (CDC), the number of individuals participating in sports in the United States continues to increase. Approximately 30 million children and young people in the United States participate in sports. This increases the risk of sports injuries for young athletes. In the United States, high school athletes caused approximately 2 million injuries, 30,000 hospitalizations, and 500,000 medical visits. Every year, more than 3.5 million children under the age of 14 receive treatment for sports injuries.

In recent years, PRP has been widely used in clinical settings. He has gained great attention in the field of cosmetic surgery. Plastic surgeons and dermatologists use the natural healing properties of platelets to improve the appearance and overall health of the skin. Several studies have evaluated the use of platelet-rich plasma in facial rejuvenation and reported positive aesthetic effects.

These treatments have been shown to improve the volume, tone and texture of the skin, and reduce the appearance of wrinkles. The application of platelet-rich plasma in dentistry and oral surgery has shown promising results. PRP has been recommended to control osteonecrosis of the jaw associated with bisphosphonates to improve wound healing and bone maturation. In addition, the use of PRP protocol and tooth extraction in the alveolar cavity has been shown to accelerate soft tissue healing and further affect the bone regeneration process.

When used in combination with other materials, platelet-rich plasma also shows better results in periodontal therapy. When these products are used alone as veneers in implant surgery, promising results have also been reported. The combination of platelet-rich plasma and necrotic bone curettage has shown encouraging results in the treatment of refractory bisphosphonate-related osteonecrosis of the jaw, as this combination provides successful results through minimally invasive surgery .

TYPE INSIGHTS:

pure platelet-rich plasma partly dominates the market, accounting for 52.8% of the 2020 revenue share. Increased its demand all over the world. Different spaces in the treatment industry have further promoted the growth of this market segment. The treatment of pure PRP effectively eliminates risks and adverse reactions such as allergies or immune reactions, which has attracted the attention of market operators. Because PRP has great potential in the treatment of various chronic diseases, its current off-label use has encouraged various manufacturers around the world to develop different types of products.

The estimated clinical benefits associated with PRP may help expand the commercialization of pure fibrin-rich, leukocyte-rich, and leukocyte-rich platelet-rich plasma-related products. Products under these categories show different mechanisms and biological characteristics, as well as differences in clinical applications.

This classification is now considered the basis of consensus, especially in the oral and maxillofacial regions. On the other hand, leukocyte-rich platelet-rich plasma is expected to grow rapidly at a compound annual growth rate of 13% between 2021 and 2028. Despite the potential risks of leukocyte-rich PRP, this market space is experiencing a significant increase in the number of business groups and experimental systems, and expanding its potential applications in orthopedics, general and sports medicine. These factors may promote LR-PRP at the fastest rate during the forecast period.

APPLICATION PROSPECTS:

The orthopedics department dominates the platelet-rich plasma market and will have the largest revenue share in 2020, at 30%. According to various studies, PRP is the most effective in treating chronic tendon lesions, and they may accelerate the healing process. Compared with traditional methods, PRP injection is more convenient as an orthopedic therapy because it can stimulate healing and lead to self-regeneration and repair of degenerative tissues.

In addition, the combination of surgical techniques and liquid PRP in orthopedic surgery enables a wide range of treatment strategies. Injury management in this area. Using platelet-rich plasma as a healing and biostimulant combined with physical therapy helps prevent disease progression and improves function in a shorter time. In addition, some of the benefits of PRP, such as long-lasting relief, improved healing after surgery, soft tissue reconstruction, and bone reconstruction and enhancement, are some factors that supplement the need for orthopedic treatment.

From 2021 to 2028, the growth rate is as high as 14%. The use of autologous platelet-rich plasma has proven to be an effective way to treat diabetic ulcers and other non-healing ulcers. In addition, due to easy application, cost-effectiveness and growth factors that promote tissue healing, platelet-rich plasma treatment methods have been further established to gain great appeal. This has increased the use of PRP in various research activities in the ulcer healing line, and has promoted the growth of this market segment.

END - USE INSIGHTS:

As there are a large number of hospitals around the world offering PRP-based therapies, the hospital sector dominates the market and will account for more than 50% of the largest revenue share in 2020. Hospitals in middle-income countries mainly focus on PRP treatments for cosmetic applications. As hair loss has become a common problem, PRP has been used more and more to treat hair loss.

These treatments are cost-effective and non-surgical, and a large number of hospitals provide these treatments to patients. In addition, Fox Technology Co., Ltd., Jiangsu Kangjian Medical Equipment Co., Ltd., and Changsha Biomedical Supply Co., Ltd. provide centrifuge systems such as Clinical Prp Prf Blood Gel Card Centrifuge for the hospital environment. With increasing adoption of PRP treatment, hospitals are expected to generate more revenue in the next few years. The clinical sector is driven by the growing medical tourism in countries such as Mexico, China and Costa Rica.

Mexico is one of the emerging countries with a growing medical tourism market. Russald Clinic and R3 Stem Cell are some of the clinics in Mexico that provide PRP therapy to support medical tourism in the country. Services provided by these clinics include PRP treatments for hair loss, facial surgery, shoulder surgery, and erectile dysfunction. The cost reduction of each clinic is an important factor driving the growth of this market segment.

REGIONAL INSIGHTS:

North America will dominate the market in 2020, accounting for the largest revenue share at 44%. This can be attributed to increased awareness of platelet-rich plasma treatments in the region, technological advances, and an increase in the number of cosmetic procedures. The active participation of academic and research institutions such as the Yale University School of Medicine and the Springfield School of Health Care, Management and Technology in evaluating the application of platelet-rich plasma therapy has further accelerated the market growth in the region.

Regulators are further promoting the growth of the North American market. The US FDA Biological Products Research and Evaluation Center is the regulatory agency responsible for platelet-rich plasma products. CBER Grants 510 (k) applies to approve the commercialization of platelet-rich plasma preparation systems in the United States. Therefore, the strong research and commercial foundation of platelet-rich plasma therapy is promoting the growth of the market in this region.

. In countries such as South Korea, India, and Thailand, an increasing number of cosmetic procedures to improve facial features are expected to drive market growth in the region. In addition, the growing medical tourism industry in the region is expected to drive market adoption. In addition, academic research institutions such as the University of Tsukuba and Guangzhou University of Traditional Chinese Medicine have actively participated in evaluating the application of platelet-rich plasma therapy.

MAJOR COMPANIES AND MARKET SHARE PROSPECTS:

The expansion of PRP treatment applications has created profitable opportunities for industry participants engaged in the development of PRP treatment solutions and services, which are designed to address specific areas of wound care, including healing ulcers. Market entities actively participate in strategic acquisitions to strengthen market influence.

For example, in February 2020, EmCyte completed the acquisition of Cellmedix Holdings LLC, which owns all the assets of the latters US company, including its proprietary product system Platelet Concentrator.Centrepid. This strategic acquisition aims to expand EmCyts product development expertise and the companys IP profile. Some of the major players in the platelet-rich plasma market include: DePuy Synthes, Zimmer Biomet, Stryker, EmCyte Corporation, Terumo BCT, Inc.; Arthrex, Inc. Dr. PRP America, JuventixAPEX, Biologix, Celling BioSciences.

MARKET SEGMENTS COVERED BY THE REPORT:

This report forecasts global, regional and national revenue growth, and analyzes the latest industry trends in each market segment from 2022 to 2030. For the purpose of this research, Grand View Research has segmented the global platelet rich plasma market report based on type, application, end use and region: Prospect type (revenue, million dollars, 2022 to 2030) pure platelet rich plasma rich Plasma rich in white blood cells and platelets Other application prospects (income, million dollars, 2022 to 2030) Orthopedics Sports Medicine Cosmetic Surgery Dermatology Ulcer Healing Venous Ulcer Traumatic Ulcer Diabetic Ulcer Pyoderma gangrenoe Nutritional Ulcer Vasculitis Ulcer other other ophthalmic ulcer surgery.

Geography Analysis:

The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

• North America (U.S. & Canada) Market Size, Y-O-Y Growth, Market Players Analysis & Opportunity Outlook
• Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
• Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market Size, Y-O-Y Growth Market Players Analys  & Opportunity Outlook
• Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market Size, Y-O-Y Growth & Market Players Analysis & Opportunity Outlook
• Middle East and Africa  (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market Size, Y-O-Y Growth Market Players Analysis & Opportunity Outlook

.